Edwards Lifesciences EW has announced one-year, real-world data on its SAPIEN 3 ... in the TAVR Market Per a research report, the global TAVR market was valued at $6.3 billion in 2023 and is ...

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Over the past few quarters, TAVR sales have been driven by the strong performance of the Edwards SAPIEN 3 Ultra valve in the United States, Europe and Rest of World, the Edwards SAPIEN 3 Ultra ...

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Edwards Lifesciences introduced TAVR to the U.S. back in November 2011 when FDA approved its Sapien heart valve for ... mitral valve and tricuspid repair devices. Last year it bought a mitral ...

Transcatheter Aortic Valve Implantation: Current & Future Devices To date, most clinical experience has been gathered using the Edwards Sapien™ and the CoreValve™ systems, both of which have ...

Edwards Lifesciences (NYSE:EW) traded lower in the premarket on Thursday after Wolfe Research downgraded the heart device maker ... company's Partner 3 trial for its TAVR heart valve Sapen ...

A National Transcatheter Aortic Valve ... (creatinine > 3.0 mg/dl or preoperative renal replacement). Eligible patients were randomized to receive the second-generation Edwards SAPIEN heart ...